GlassScriptPhysician profile
William James Huffman
NPI 1518149756
$8,752.94
in general payments reported to CMS, 2019-2025
41 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,739 · 2020: $1,562 · 2021: $1,806 · 2022: $1,562 · 2023: $922 · 2024: $694 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,171.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,104.66 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $782.10 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $752.88 | 2019-2025 | Jardiance, Ofev |
| Dexcom, INC. | $685.73 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $583.97 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $437.95 | 2019-2025 | |
| Lilly USA, LLC | $412.80 | 2019-2025 | Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.87 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $287.26 | 2019-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $262.63 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $226.21 | 2019-2023 | |
| Glaxosmithkline, LLC. | $223.31 | 2020-2024 | Trelegy Ellipta, Nucala |
| Abbvie INC. | $215.52 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $192.43 | 2019-2023 | Verquvo, Steglatro, Belsomra |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.